|
Osteitis Deformans
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
However, PDB patients without SQSTM1 mutations seem to have susceptibility genetic polymorphisms in regions containing the CaSR, ESR1, TNFRSF11B (OPG), TNFRSF11A (RANK), CSF1 (M-CSF), OPTN, TM7SF4 (DC-STAMP), VCP, NUP205, RIN3, PML, and GOLGA6A genes, resulting in an increased risk of developing PDB.
|
21959292 |
2012 |
|
Schizophrenia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
A diagnosis of schizophrenia is a significant predictor for increased GLP, SETDB1 mRNA expression and H3K9me2 levels in both postmortem brain and lymphocyte samples.
|
23815974 |
2013 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
A-366 has significantly less cytotoxic effects on the growth of tumor cell lines compared to other known G9a/GLP small molecule inhibitors despite equivalent cellular activity on methylation of H3K9me2.
|
26147105 |
2015 |
|
leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Additionally, the selectivity profile of A-366 has aided in the discovery of a potentially important role for G9a/GLP in maintenance of leukemia.
|
26147105 |
2015 |
|
Childhood Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Additionally, the selectivity profile of A-366 has aided in the discovery of a potentially important role for G9a/GLP in maintenance of leukemia.
|
26147105 |
2015 |
|
Cardiomyopathies
|
0.010 |
PosttranslationalModification
|
group |
BEFREE |
In human hypertrophic hearts, BRG1-G9a/GLP-DNMT3 complex is also activated; its level correlates with H3K9/CpG methylation, Myh6 repression, and cardiomyopathy.
|
26952936 |
2016 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Significant delay in intensification of treatment by addition of insulin is observed in patients with T2DM inadequately controlled with GLP-1RA.
|
27629433 |
2017 |
|
Hyperglycemia
|
0.050 |
Biomarker
|
disease |
BEFREE |
Real world outcomes of addition or switch to insulin therapy in type 2 diabetes (T2DM) patients on glucagon-like paptide-1 receptor agonist (GLP-1RA) with inadequately controlled hyperglycaemia, are not known.
|
27629433 |
2017 |
|
Heart failure
|
0.080 |
Biomarker
|
disease |
BEFREE |
The incretin-based therapies (GLP agonists and DPP-4 inhibitors) are generally not associated with any HF interaction.
|
27653447 |
2017 |
|
Congestive heart failure
|
0.080 |
Biomarker
|
disease |
BEFREE |
The incretin-based therapies (GLP agonists and DPP-4 inhibitors) are generally not associated with any HF interaction.
|
27653447 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that a combination of exercise and GLP-1RA treatment is effective in type 2 diabetes.
|
27717126 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are registered for treatment of both obesity and type 2 diabetes.
|
27717222 |
2017 |
|
Obesity
|
0.060 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are registered for treatment of both obesity and type 2 diabetes.
|
27717222 |
2017 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated the effect of the GLP-1RA liraglutide on counterregulatory responses and GE rate during hypoglycaemia in persons with T1D.
|
27868372 |
2017 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.050 |
Biomarker
|
disease |
BEFREE |
We evaluated the effect of the GLP-1RA liraglutide on counterregulatory responses and GE rate during hypoglycaemia in persons with T1D.
|
27868372 |
2017 |
|
Anorexia
|
0.030 |
Biomarker
|
disease |
BEFREE |
The acute anorectic and glucose tolerance effects of peripherally dosed GLP-1RA exendin-4 and liraglutide were preserved in all mouse lines.
|
27908915 |
2017 |
|
Nausea and vomiting
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Asian patients may also experience higher rates of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as nausea and vomiting, compared with their Western counterparts.
|
27976513 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.100 |
Biomarker
|
disease |
BEFREE |
To compare efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in people with type 2 diabetes.
|
27981757 |
2017 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
When all GLP-1RAs were compared with each other, no clinically meaningful differences were observed in weight loss, blood pressure reduction or hypoglycaemia risk.
|
27981757 |
2017 |
|
Gastrointestinal symptom
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The RCTs in the present analysis show that all GLP-1RAs improve glycaemic control, reduce body weight and increase the risk of adverse gastrointestinal symptoms compared with placebo.
|
27981757 |
2017 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Benefits of GLP-1RAs are considered to outweigh the risks in NAFLD/NASH patients with or without diabetes.
|
28065744 |
2017 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Benefits of GLP-1RAs are considered to outweigh the risks in NAFLD/NASH patients with or without diabetes.
|
28065744 |
2017 |
|
Non-alcoholic Fatty Liver Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
We searched the MEDLINE, Embase, and Cochrane Library Central to identify randomized controlled trials (RCTs) and observational studies that compared GLP-1RAs with a control treatment or baseline values with respect to efficacy and safety in patients with NAFLD/NASH.
|
28065744 |
2017 |
|
Gastrointestinal discomfort
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
The reported major adverse events associated with GLP-1RA treatment included mild to moderate gastrointestinal discomfort that resolved within a few weeks.
|
28065744 |
2017 |
|
Steatohepatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
GLP-1RA treatment produced significant reductions relative to baseline in liver histology scores for steatosis (MD, 0.80; 95% CI, 0.49 to 1.11), lobular inflammation (MD, 0.22; 95% CI, 0.00 to 0.45), hepatocellular ballooning (MD, 0.41; 95% CI, 0.15 to 0.67) and fibrosis (MD, 0.35; 95% CI, 0.00 to 0.70).
|
28065744 |
2017 |